Janssen Biotech, a subsidiary of Johnson and Johnson, won the US FDA's approval on 18 July to market the firm's infusible formulation of golimumab under the brand-name Simponi Aria in combination with methotrexate to treat adults with moderately to severely active rheumatoid arthritis (RA).
The medicine is the first and only fully-human anti-tumor necrosis factor (TNF)-alpha infusible therapy marketed in the US, the company...